Vera Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $78,225 | $68,993 |
| General and administrative | 23,787 | 21,910 |
| Total operating expenses | 102,012 | 90,903 |
| Loss from operations | (102,012) | (90,903) |
| Other income (expense): | ||
| Interest income | 7,979 | 1,750 |
| Interest expense | (3,786) | (992) |
| Other income | 1,877 | 1,899 |
| Change in fair value of non-marketable equity securities | (47) | (809) |
| Total other income | 6,023 | 1,848 |
| Loss before provision for income taxes | (95,989) | (89,055) |
| Provision for income taxes | (1) | (1) |
| Net loss | $(95,990) | $(89,056) |
| Other comprehensive loss: | ||
| Change in unrealized gain (loss) on marketable securities | 251 | (224) |
| Comprehensive loss | $(95,739) | $(89,280) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.25) | $(3.35) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 42,707,072 | 26,570,676 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.